The downgrade from Buy to Neutral by a reputable analyst firm like HC Wainwright & Co. suggests a less favorable view on Longboard Pharmaceuticals' stock performance. The reduction in the price target from $80 to $60 further indicates a decreased expectation of the company's future stock price, likely leading to a negative short-term impact on the stock.